UK biotech firms eye Nasdaq listings

By Aidan Gregory
19 Jan 2021

Immunocore, the UK biotech company, has filed for an IPO on the Nasdaq in New York following a $75m series ‘C’ funding round which concluded last week.

The Oxford-based company is developing immunotherapy treatments that harness the power of the body’s T cell receptors to fight diseases such as cancer. It has so far raised over $800m in private funding, including the $75m series C financing this month, which included an investment from BlackRock.


Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial